MedTrace Logo

Detection of Cerebral Proteinopathy in Alzheimer's Disease Through Magnetic Resonance Imaging

NCT03846232 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2023-03-31

No results posted yet for this study

Summary

The main goal of the T1rho/BBRC2017 study is to assess the capability of the MRI sequences T1rho + multicomponent T2 relaxation analysis of detecting abnormal cerebral protein deposition in AD patients in comparison with an age-matched cognitively healthy control group. Both the AD and control groups will had previously undergone amyloid PET imaging to confirm/discard cerebral proteinopathy in the context of other research studies.

Conditions

  • Alzheimer Disease

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • Hospital Clinic of Barcelona

    collaborator OTHER

  • Barcelonabeta Brain Research Center, Pasqual Maragall Foundation

    lead OTHER

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-12
Primary Completion
2020-11-30
Completion
2022-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03846232 on ClinicalTrials.gov